Trial Profile
The Pathogenic Role of 11ß-hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Glucose intolerance; Metabolic syndrome
- Focus Pharmacodynamics
- 11 Jan 2018 Status changed from recruiting to completed.
- 23 Oct 2006 New trial record.